Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension

Background Recent randomised trials showed benefit for anti-inflammatory therapies in coronary disease but excluded stroke. The prognostic value of blood inflammatory markers after stroke is uncertain and guidelines do not recommend their routine measurement for risk stratification. Methods We performed a systematic review and meta-analysis of studies investigating the association of C-reactive protein (CRP), interleukin-6 (IL-6) and fibrinogen and risk of recurrent stroke or major vascular events (MVEs). We searched EMBASE and Ovid Medline until 10/1/19. Random-effects meta-analysis was performed for studies reporting comparable effect measures. Results Of 2,515 reports identified, 39 met eligibility criteria (IL-6, n = 10; CRP, n = 33; fibrinogen, n = 16). An association with recurrent stroke was reported in 12/26 studies (CRP), 2/11 (fibrinogen) and 3/6 (IL-6). On random-effects meta-analysis of comparable studies, CRP was associated with an increased risk of recurrent stroke [pooled hazard ratio (HR) per 1 standard-deviation (SD) increase in loge-CRP (1.14, 95% CI 1.06–1.22, p < 0.01)] and MVEs (pooled HR 1.21, CI 1.10–1.34, p < 0.01). Fibrinogen was also associated with recurrent stroke (HR 1.26, CI 1.07–1.47, p < 0.01) and MVEs (HR 1.31, 95% CI 1.15–1.49, p < 0.01). Trends were identified for IL-6 for recurrent stroke (HR per 1-SD increase 1.17, CI 0.97–1.41, p = 0.10) and MVEs (HR 1.22, CI 0.96–1.55, p = 0.10). Conclusion Despite evidence suggesting an association between inflammatory markers and post-stroke vascular recurrence, substantial methodological heterogeneity was apparent between studies. Individual-patient pooled analysis and standardisation of methods are needed to determine the prognostic role of blood inflammatory markers and to improve patient selection for randomised trials of inflammatory therapies.

Download Full-text

Baseline high-sensitivity C-reactive protein to predict progression-free survival in metastatic renal cell carcinoma patients treated with first-line sunitinib.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e15527 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e15527-e15527

Author(s):

Ryuichi Mizuno ◽

Go Kimura ◽

Tsunenori Kondo ◽

Takeshi Ueda ◽

Hidehiko Hara ◽

...

Keyword(s):

Interleukin 6 ◽

Inflammatory Markers ◽

Progression Free Survival ◽

High Sensitivity ◽

C Reactive Protein ◽

First Line ◽

Free Survival ◽

Reactive Protein ◽

Hs Crp ◽

Serum Inflammatory Markers

e15527 Background: Predicting the efficacy of tyrosine kinase inhibitors (TKI) would be of clinical value in patients with metastatic renal cell carcinoma (mRCC). We tested the hypothesis that serum inflammatory markers are associated with clinical outcome in mRCC patients at favorable or intermediate prognostic risk treated with first-line sunitinib. Methods: Eighty-nine mRCC patients were prospectively monitored at baseline (day 0) during sunitinib treatment. Serum interleukin-6 and 8 levels were determined by CLEIA and ELISA, respectively. A high-sensitivity C-reactive protein (hs-CRP) levels were measured using laser nephelometry. Correlations between baseline interleukin-6, 8, hs-CRP levels and response to sunitinib, and progression-free survival (PFS) were examined. Results: Median PFS was 9.2 months. Clinical benefit rate (CBR; percent complete responses+partial responses +stable disease 24 weeks) was 57.3%. Baseline interleukin-8 (P=0.0240) and hs-CRP (P=0.0060) was associated with CBR. No association between baseline interleukin-6 and 8 with PFS was observed. However, baseline hs-CRP were associated with PFS (P=0.0016; unit risk 1.010; 95% CI 1.004 to 1.017). Conclusions: Baseline serum inflammatory markers could be of clinical interest in sunitinib-treated mRCC patiens to predict outcome. Baseline hs-CRP serum levels warrant further study. Clinical trial information: UMIN000009622.

Download Full-text

Inflammatory Markers-Serum Level of C-Reactive Protein, Tumor Necrotic Factor-α, and Interleukin-6 as Predictors of Outcome for Peripartum Cardiomyopathy

The Journal of Obstetrics and Gynecology of India ◽

10.1007/s13224-013-0428-9 ◽

2013 ◽

Vol 63 (4) ◽

pp. 234-239 ◽

Cited By ~ 16

Author(s):

A. Sarojini ◽

A. Sai Ravi Shanker ◽

M. Anitha

Keyword(s):

Serum Level ◽

Interleukin 6 ◽

Inflammatory Markers ◽

Peripartum Cardiomyopathy ◽

Predictors Of Outcome ◽

C Reactive Protein ◽

Reactive Protein ◽

Factor Α

Download Full-text

The Role of C-reactive Protein and Interleukin 6 in the Cases of Preeclampsia Associated with Obesity

Revista de Chimie ◽

10.37358/rc.19.3.7011 ◽

2019 ◽

Vol 70 (3) ◽

pp. 805-808 ◽

Cited By ~ 1

Author(s):

Izabella Petre ◽

Marius Craina ◽

Nicolae Suciu ◽

Alina Sisu ◽

Radu Dumitru Moleriu ◽

...

Keyword(s):

Risk Factor ◽

Early Detection ◽

Pregnant Women ◽

Interleukin 6 ◽

Inflammatory Markers ◽

Inflammatory Condition ◽

European Level ◽

C Reactive Protein ◽

Reactive Protein

In the management of preeclampsia/eclampsia, it would be useful at least at European level, to have clear protocols for early detection and approach of cases with hypertension, as well as to create an algorithm to identify the predisposition to hypertensive pregnancy pathology. The aim has been to identify the favorable factors and the evolution of the pregnancy in the 100 patients admitted to the obstetrics clinic between January 2014 and December 2018, aged between 15-44 years, who have been diagnosed with preeclampsia. In recent years, the management of pregnant women with preeclampsia has improved a lot due to a better understanding of the pathogenesis and a refinement of adequate pregnancy monitoring. Obesity has been shown to be a risk factor in preeclampsia. Several studies have identified preeclampsia as an inflammatory condition. A large number of inflammatory markers, such as C-reactive protein (PCR) and Interleukin 6 (IL-6), have been shown to be elevated in pregnant women with preeclampsia.

Download Full-text

505 INTERLEUKIN-6, C-REACTIVE PROTEIN, FIBRINOGEN, AND RISK OF RECURRENCE AFTER ISCHEMIC STROKE: SYSTEMATIC REVIEW AND META-ANALYSIS

Age and Ageing ◽

10.1093/ageing/afab117.09 ◽

2021 ◽

Vol 50 (Supplement_2) ◽

pp. ii1-ii4

Author(s):

J J McCabe ◽

E O’Reilly ◽

S Coveney ◽

J Harbison ◽

R Collins ◽

...

Keyword(s):

Systematic Review ◽

Random Effects ◽

Interleukin 6 ◽

Inflammatory Markers ◽

Recurrent Stroke ◽

Meta Analysis ◽

Randomised Trials ◽

C Reactive Protein ◽

Vascular Events ◽

Reactive Protein

Abstract Background Recent randomised trials showed benefit for anti-inflammatory therapies in coronary disease but excluded stroke. The prognostic value of blood inflammatory markers after stroke is uncertain and guidelines do not recommend their routine measurement for risk stratification. Methods We performed a systematic review and meta-analysis of studies investigating the association of C-reactive protein (CRP), interleukin-6 (IL-6) and fibrinogen and risk of recurrent stroke or major vascular events (MVEs). We searched EMBASE and Ovid Medline until 10/1/19. Random-effects meta-analysis was performed for studies reporting comparable effect measures. Results Of 2,515 reports identified, 39 met eligibility criteria (IL-6, n = 10; CRP, n = 33; fibrinogen, n = 16). An association with recurrent stroke was reported in 12/26 studies (CRP), 2/11 (fibrinogen) and 3/6 (IL-6). On random-effects meta-analysis of comparable studies, CRP was associated with an increased risk of recurrent stroke [pooled hazard ratio (HR) per 1 standard-deviation (SD) increase in loge-CRP (1.14, 95% CI 1.06-1.22, p < 0.01)] and MVEs (pooled HR 1.21, CI 1.10-1.34, p < 0.01). Fibrinogen was also associated with recurrent stroke (HR 1.26, CI 1.07-1.47, p < 0.01) and MVEs (HR 1.31, 95% CI 1.15-1.49, p < 0.01). Trends were identified for IL-6 for recurrent stroke (HR per 1-SD increase 1.17, CI 0.97-1.41, p = 0.10) and MVEs (HR 1.22, CI 0.96-1.55, p = 0.10). Conclusion Despite evidence suggesting an association between inflammatory markers and post-stroke vascular recurrence, substantial methodological heterogeneity was apparent between studies. Individual-patient pooled analysis and standardisation of methods are needed to determine the prognostic role of blood inflammatory markers and to improve patient selection for randomised trials of inflammatory therapies.

Download Full-text

Comparison of serum concentrations of C-reactive protein, TNF-α, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2003.10.007 ◽

2004 ◽

Vol 64 (2) ◽

pp. 99-106 ◽

Cited By ~ 46

Author(s):

K.M. Choi ◽

J. Lee ◽

K.W. Lee ◽

J.A. Seo ◽

J.H. Oh ◽

...

Keyword(s):

Glucose Tolerance ◽

Impaired Glucose Tolerance ◽

Interleukin 6 ◽

Korean Women ◽

Serum Concentrations ◽

C Reactive Protein ◽

Reactive Protein ◽

Tnf Α

Download Full-text

The role of inflammatory biomarkers in CHD-associated pulmonary hypertension in children

Cardiology in the Young ◽

10.1017/s1047951116000408 ◽

2016 ◽

Vol 27 (2) ◽

pp. 255-260 ◽

Cited By ~ 2

Author(s):

Gokcen Oz-Tuncer ◽

Rana Olgunturk ◽

Ayhan Pektas ◽

Erman Cilsal ◽

Serdar Kula ◽

...

Keyword(s):

Pulmonary Hypertension ◽

Ejection Fraction ◽

Interleukin 6 ◽

Inflammatory Markers ◽

Healthy Children ◽

C Reactive Protein ◽

Reactive Protein ◽

Hypertension In Children ◽

Fractional Shortening

AbstractObjectiveThe present study aims to identify the role of inflammatory markers such as C-reactive protein, interleukin-6, and fractalkine in CHD-associated pulmonary hypertension in children.MethodsThis is a prospective review of 37 children with CHD-related pulmonary hypertension, 21 children with congenital heart defects, and 22 healthy children.ResultsSerum C-reactive protein and interleukin-6 levels were significantly higher in the children with CHD-related pulmonary hypertension (respectively, p=0.049 and 0.026). Serum C-reactive protein concentrations correlated negatively with ejection fraction (r=−0.609, p=0.001) and fractional shortening (r=−0.452, p=0.007) in the pulmonary hypertension group. Serum fractalkine concentrations correlated negatively with ejection fraction (r=−0.522, p=0.002) and fractional shortening (r=−0.395, p=0.021) in the children with pulmonary hypertension. Serum interleukin-6 concentrations also correlated negatively with Qs (r=−0.572, p=0.021), positively with Rs (r=0.774, p=0.001), and positively with pulmonary wedge pressure (r=0.796, p=0.006) in the pulmonary hypertension group. A cut-off value of 2.2 IU/L for C-reactive protein was able to predict pulmonary hypertension with 77.5% sensitivity and 77.5% specificity. When the cut-off point for interleukin-6 concentration was 57.5 pg/ml, pulmonary hypertension could be predicted with 80% sensitivity and 75% specificity.ConclusionInflammation is associated with the pathophysiology of pulmonary hypertension. The inflammatory markers C-reactive protein and interleukin-6 may have a role in the clinical evaluation of paediatric pulmonary hypertension related to CHDs.

Download Full-text

Inflammatory Markers and Hepcidin are Elevated but Serum Iron is Lower in Obese Women of Reproductive Age

Nutrients ◽

10.3390/nu13010217 ◽

2021 ◽

Vol 13 (1) ◽

pp. 217

Author(s):

Sixtus Aguree ◽

Manju B. Reddy

Keyword(s):

Total Cholesterol ◽

Interleukin 6 ◽

Inflammatory Markers ◽

Serum Iron ◽

Serum Lipids ◽

Normal Weight ◽

Obese Women ◽

C Reactive Protein ◽

Childbearing Age ◽

Reactive Protein

Limited evidence suggests that serum iron and hepcidin concentrations are dysregulated in obesity and inflammation. The objective of the present study was to compare C-reactive protein, interleukin-6, circulating levels of hepcidin, serum lipids, and iron status in obese vs. normal-weight women of childbearing age. Healthy women aged 18–30 years were recruited for the study (n = 47: 25 obese and 22 normal weight). Fasting blood samples were obtained to measure serum lipids (total cholesterol, HDL, LDL cholesterol, triglycerides, non-HDL cholesterol), complete blood count, serum iron, total iron-binding capacity, transferrin saturation, serum ferritin, hepcidin, C-reactive protein, and interleukin-6. Obese women had significantly higher mean serum C-reactive protein (p < 0.001), interleukin-6 (p < 0.001), hepcidin (p = 0.024), triglycerides (p < 0.001) and total cholesterol/HDL ratio (p < 0.001) but lower HDL (p = 0.001) and serum iron/hepcidin ratio (p = 0.011) compared with normal-weight women. BMI correlated positively with inflammatory markers, triglycerides, LDL and total cholesterol/HDL ratio, and negatively with HDL and serum iron/hepcidin ratio. Serum iron correlated negatively with ferritin in the obese group (p = 0.030) but positively in normal weight women (p = 0.002). BMI and ferritin were the only predictors of serum iron/hepcidin ratio accounting for 23% of the variation among subjects. Studies are needed to examine anti-inflammatory dietary approaches that can improve iron biomarkers in obese women.

Download Full-text

Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis

Psychological Medicine ◽

10.1017/s0033291712000128 ◽

2012 ◽

Vol 42 (10) ◽

pp. 2015-2026 ◽

Cited By ~ 112

Author(s):

S. A. Hiles ◽

A. L. Baker ◽

T. de Malmanche ◽

J. Attia

Keyword(s):

Interleukin 6 ◽

Inflammatory Markers ◽

Antidepressant Treatment ◽

Inflammatory Marker ◽

Meta Analysis ◽

Interleukin 10 ◽

Cochrane Library ◽

C Reactive Protein ◽

Cross Sectional ◽

Reactive Protein

BackgroundCross-sectional studies support an association between depression and inflammatory markers. However, little is known of their relationship in the context of antidepressant treatment. Our aim was to explore via meta-analysis whether antidepressant treatment is associated with a reduction in three inflammatory markers associated with depression.MethodA computerized search of EMBASE, Medline, PsycINFO and Cochrane Library databases was completed using subject headings for depression and either interleukin-6, C-reactive protein or interleukin-10, selecting studies which reported circulating levels of inflammatory markers before and after antidepressant treatment for people with depression. Outcome and moderator variables were coded for analysis, including inflammatory marker change, depression severity change, age, gender ratio, assay brand, treatment response and weight change.ResultsPooled effect sizes showed a significant decrease in interleukin-6 (n=14, d=−0.42, p=0.02), marginally significant decrease in C-reactive protein (n=8, d=−0.57, p=0.05) and a non-significant decrease in interleukin-10 (n=3, d=−0.45, p=0.14) after treatment. High levels of heterogeneity were observed, which may be associated with clinical variations between the studies such as weight gain, anxiety, incomplete remission and other individual differences and co-morbidities.ConclusionsThe findings of this meta-analysis indicate that there may be a normalization of overactive inflammatory processes following antidepressant treatment.

Download Full-text